Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991065 | 0.80 | PNMT (0.61) | IDO1PNMTTAAR1SIGMAR1IGF1R | |
| SCHEMBL2098325 | 0.78 | MAPT (0.41) | IDO1PNMTTAAR1SMN1; SMN2NPC1 | |
| SCHEMBL42420 | 0.78 | PIK3CA (0.44) | IDO1PNMTTAAR1SMN1; SMN2NPC1 | |
| SCHEMBL638304 | 0.78 | TSHR (0.50) | IDO1PNMTTAAR1SMN1; SMN2NPC1 | |
| SCHEMBL3298586 | 0.78 | IDO1 (0.64) | IDO1PNMTTAAR1SMN1; SMN2LMNA | |
| SCHEMBL29494831 | 0.76 | IDO1 (0.61) | IDO1PNMTTAAR1SMN1; SMN2NPC1 | |
| SCHEMBL407334 | 0.76 | IDO1 (0.61) | IDO1PNMTTAAR1SMN1; SMN2NPC1 | |
| SCHEMBL17372921 | 0.76 | IDO1 (0.61) | IDO1PNMTTAAR1SMN1; SMN2NPC1 | |
| SCHEMBL1780435 | 0.75 | IDO1 (0.54) | IDO1PNMTTAAR1SMN1; SMN2NPC1 | |
| SCHEMBL5847393 | 0.75 | L3MBTL1 (0.39) | IDO1SMN1; SMN2NPC1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| US-20080090847-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | PLIVA D.D. (HR) | 2008-04-17 | — | — | US | claimed |
| EP-1432713-A4 | FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS | ESSENTIAL THERAPEUTICS INC (US) | 2005-05-11 | — | — | EP | claimed |
| EP-1411949-A4 | 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | ESSENTIAL THERAPEUTICS INC (US) | 2004-11-24 | — | — | EP | claimed |
| EP-1432713-A2 | FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS | Essential Therapeutics, Inc. (US) | 2004-06-30 | — | — | EP | claimed |
| EP-1411949-A2 | 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | Essential Therapeutics, Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| US-20030181470-A1 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | ESSENTIAL THERAPEUTICS, INC. | 2003-09-25 | — | — | US | claimed |
| US-20030176436-A1 | Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof | ALA PAUL J (DE) | 2003-09-18 | — | — | US | claimed |
| US-6417195-B1 | LIBRARIES AND COMBINATORIAL CHEMISTRY | LION BIOSCIENCE AG (DE) | 2002-07-09 | — | — | US | claimed |
| EP-1155001-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2001-11-21 | — | — | EP | claimed |
| WO-2001041763-A1 | TREATMENT OF ADDICTION DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-06-14 | — | — | WO | claimed |
| WO-2000050406-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2000-08-31 | — | — | WO | claimed |
| EP-1019367-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-07-19 | — | — | EP | claimed |
| EP-0863877-A4 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INST (US) | 1999-07-21 | — | — | EP | claimed |
| US-5874443-A | BIOSYNTHESIS | TREGA BIOSCIENCES, INC. (US) | 1999-02-23 | — | — | US | claimed |
| WO-1999007672-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-02-18 | — | — | WO | claimed |
| EP-0863877-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1998-09-16 | — | — | EP | claimed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | IDO1 481/4885PNMT 3102/4885TAAR1 1127/4885 |
| US-20030181470-A1 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | AAAS, ALAD, NAALAD2 | IDO1 841/4885PNMT 2140/4885TAAR1 4400/4885 |
| US-20030176436-A1 | Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof | DHFR, DHODH, DPYD | IDO1 113/4885PNMT 819/4885TAAR1 2987/4885 |
| US-20080090847-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | AAAS, ALAD, NAALAD2 | IDO1 841/4885PNMT 2140/4885TAAR1 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.